1-8 of 8
Muntasir M. Majumder
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Ken Flanagan, PhD, Muntasir M Majumder, MSc, BPharm, Romika Kumari, PhD, Juho Miettinen, PhD, Ana Slipicevic, PhD, Sarah A. Holstein, MD PhD, Michelle L. Varney, MS, Minna Suvela, MSC, Fredrik Lehmann, PhD, Nina N. Nupponen, PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3100.
https://doi.org/10.1182/blood-2019-125952
Published: 2019
Journal Articles

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Muntasir M Majumder, MSc, BPharm, Maija Leppä, MSc(Tech), Monica Hellesoy, PhD, Paul Dowling, BSc, PhD, Alina Malyutina, Despina Bazou, BSc, MSc, PhD, Emma Irene Andersson, MSc, Alun Parsons, Jing Tang, PhD, Olli Kallioniemi, MD PhD, Satu Mustjoki, MDPhD, Peter O'Gorman, MD PhD FRCP, FRCPath, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Bjorn Gjertsen, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 264.
https://doi.org/10.1182/blood-2018-99-118242
Published: 2018
Journal Articles

Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing Allows Identification of Physiologically Distinct Sub-Clones That Can Inform Therapeutic and Drug Development Strategies

Despina Bazou, BSc, MSc, PhD, Muntasir M Majumder, MSc, BPharm, Ciara Tierney, BSc, Sinead O'Rourke, BSc, Pekka Anttila, MD, Raija Helena Silvennoinen, MD PhD, Caroline A Heckman, PhD, Paul Dowling, BSc, PhD, Peter O'Gorman, MD PhD FRCP, FRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 1901.
https://doi.org/10.1182/blood-2018-99-115910
Published: 2018
Journal Articles

A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines

Raija Helena Silvennoinen, MDPhD, Dimitrios Tsallos, BSc(Hons),MSc, Hareth Nahi, MD PhD, Pekka Anttila, MD, Perttu Koskenvesa, MD, Juha Lievonen, MD, Anu Räsänen, MD, Ville Varmavuo, MD PhD, Anu Sikiö, MD, Marita Nurmi, MD, Marjaana Säily, MD PhD, Anu Partanen, MD, Marja Sankelo, MDPhD, Sini Luoma, MD, Sorella Ilveskero, MD PhD, Tarja-Terttu Pelliniemi, MD PhD, Esa Jantunen, MD PhD, Muntasir M Majumder, MSc, BPharm, Samuli Eldfors, PhD, Maija Leppä, MSc(Tech), Caroline A Heckman, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1975.
https://doi.org/10.1182/blood-2018-99-114593
Published: 2018
Journal Articles

Midostaurin Shows Efficacy in Refractory Multiple Myeloma with TP53 Mutation and Elevated Expression of NTRK1, NTRK3 and AURKA

Muntasir M Majumder, MSc, BPharm, David Tamborero, PhD, Pekka Anttila, Raija Helena Silvennoinen, MD, Samuli Eldfors, MSc, Juha Lievonen, Ashwini Kumar, MRes, Alun Parsons, Minna Suvela, MSC, Esa Jantunen, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4412.
https://doi.org/10.1182/blood.V130.Suppl_1.4412.4412
Published: 2017
Journal Articles

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML

Riikka Karjalainen, Tea Pemovska, Mihaela Popa, Minxia Liu, Komal K. Javarappa, Muntasir M. Majumder, Bhagwan Yadav, David Tamborero, Jing Tang, Dmitrii Bychkov, Mika Kontro, Alun Parsons, Minna Suvela, Mireia Mayoral Safont, Kimmo Porkka, Tero Aittokallio, Olli Kallioniemi, Emmet McCormack, Bjørn T. Gjertsen, Krister Wennerberg, Jonathan Knowles, Caroline A. Heckman
Journal: Blood
Blood (2017) 130 (6): 789–802.
https://doi.org/10.1182/blood-2016-02-699363
Published: 2017
Includes: Supplemental data
Journal Articles

Simultaneous Monitoring of Drug Responses on Distinct Hematopoietic Cell Populations Allow Assessment of Direct and Indirect Cytotoxic Effects of Targeted Therapies

Muntasir M Majumder, MSc, MPharm, Aino Maija Leppä, BSc, Caroline A Heckman, PhD
Journal: Blood
Blood (2016) 128 (22): 3515.
https://doi.org/10.1182/blood.V128.22.3515.3515
Published: 2016
Journal Articles

DNA Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors

Muntasir M Majumder, MSc, MPharm, David Tamborero, PhD, Pekka Anttila, MD, Raija Silvennoinen, MD, Samuli Eldfors, MSc, Ashwini Kumar, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Esa Jantunen, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2016) 128 (22): 198.
https://doi.org/10.1182/blood.V128.22.198.198
Published: 2016